Variable absorption of carbidopa affects both peripheral and central levodopa metabolism.
Level 4 - case-series / case-control
Small single-arm pharmacokinetic study without a separate control group
PubMed 10934669 · doi:10.1177/00912700022009585
What was done
Nine patients with Parkinson disease were given 50 mg oral carbidopa followed 1 hour later by an intravenous infusion of 150 mg stable isotope-labeled levodopa. Eight patients underwent lumbar puncture at 6 hours post-infusion. Blood and cerebrospinal fluid (CSF) samples were analyzed by high-performance liquid chromatography and mass spectrometry. Participants were divided post hoc into slow and rapid carbidopa absorption groups.
What was found
Poor carbidopa absorbers had significantly greater peripheral levodopa decarboxylation measured by serum-labeled HVA AUC (p = 0.05). Elimination half-lives of serum levodopa did not differ between groups. Serum carbidopa AUC correlated with percent-labeled HVA in CSF (R = 0.786, p = 0.02). Rapid absorbers had higher percent-labeled CSF HVA compared to slow absorbers (60% vs. 49%, p = 0.02).
Why it matters
This indicates that standard clinical doses of carbidopa do not saturate peripheral aromatic L-amino acid decarboxylase, meaning variations in carbidopa absorption can alter central dopamine availability.
Limits
The sample size is very small (n=9 total, n=8 with CSF data). The split into absorption categories was non-randomized and observational, and clinical Parkinsonian motor outcomes were not assessed.
Cited by
- supports Carbidopa blocks peripheral metabolism of levodopa, preventing it from converting into dopamine before crossing into the brain.